AZD9291-induced Acute Interstitial Lung Disease.
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
Ke-Ke
KK
Nie
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
Xiao
X
Zou
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
Chuan-Xin
CX
Geng
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
Ling
L
Zhang
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
Shi-Chao
SC
Liu
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
Chun-Ling
CL
Zhang
Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.
You-Xin
YX
Ji
D000178:Acrylamides / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000814:Aniline Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D007211:Indoles; D011743:Pyrimidines
D000178:Acrylamides; D000814:Aniline Compounds; C000596361:osimertinib; D007211:Indoles; D011743:Pyrimidines